Please login to the form below

Not currently logged in
Email:
Password:

tolvaptan

This page shows the latest tolvaptan news and features for those working in and with pharma, biotech and healthcare.

AZ, BMS and Boehringer among UK Prix Galien finalists

AZ, BMS and Boehringer among UK Prix Galien finalists

tolvaptan. Jinarc. Otsuka. Polycystic kidney disease. nintedanib. Ofev. Boehringer Ingelheim. Idiopathic pulmonary fibrosis.

Latest news

  • New cancer meds and drug extensions top CHMP recommendations New cancer meds and drug extensions top CHMP recommendations

    The CHMP, the drug safety and efficacy arm of the EMA, has recommended approval for Otsuka's Jinarc (tolvaptan) for the treatment of patients with autosomal dominant polycystic kidney disease (ADPKD),

  • Jinarc backed for European approval in rare kidney disease Jinarc backed for European approval in rare kidney disease

    The European Medicines Agency has recommended granting a marketing authorisation to Otsuka's orphan drug Jinarc (tolvaptan). ... The CHMP says that while no cases of liver failure were found in Otsuka's latest trial, it “ is possible that in a wider

  • Otsuka launches European ADPKD forum Otsuka launches European ADPKD forum

    Otsuka's interests in the area include the treatment Samsca (tolvaptan), which was turned down last year by the FDA for use as an ADPKD treatment, but is approved in Japan

  • Japanese product news in brief Japanese product news in brief

    Otsuka has launched a 30mg tablet formulation of Samsca (tolvaptan), its drug to treat autosomal dominant polycystic kidney disease (ADPKD), which should make the therapy easier for patients to take. ... Tolvaptan is a first-in-class vasopressin

  • Otsuka's Samsca heads clutch of Japanese approvals

    Samsca (tolvaptan) is the first approved treatment anywhere in the world for autosomal dominant polycystic kidney disease (PKD), which is characterised by the proliferation of fluid-filled cysts in the kidneys

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics